Preferred Label : Synthetic Vaccine Particles-Rapamycin;
NCIt synonyms : SVP-R; SVP-Rapamycin; SVP-Rapa;
NCIt definition : A proprietary, biodegradable, poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based
formulation composed of synthetic vaccine particles (SVP) encapsulating the macrolide
antibiotic rapamycin (SVP-R), with immunosuppressant and drug-protective activities.
Upon administration of SVP-R, the SVP moiety is selectively and preferentially taken
up through endocytosis by antigen-presenting cells (APCs), located in the spleen and
lymph nodes, specifically dendritic cells (DCs). Rapamycin, a mammalian target of
rapamycin (mTOR) inhibitor, prevents DC maturation, induces tolerogenic DCs, induces
regulatory T-cells (Tregs), blocks activation of effector T-cells, induces B-cell
tolerance, reduces B-cell activation, and prevents antibody formation, thereby inducing
immune tolerance. When co-administered with a biological immunogenic drug known to
induce the production of anti-drug antibodies (ADA), SVP-R is able to prevent ADA
formation, which prevents the unwanted neutralizing effects of ADAs, increases efficacy
of the biological drug, and permits sustained therapeutic activity and repeated administration
of the biological drug. In the presence of a specific target antigen, SVP-R is able
to prevent an antigen-specific immune response and induces antigen-specific immune
tolerance. Compared to the administration of free rapamycin, SVP-R induces long-lasting
immunological tolerance.;
Molecule name : SEL-110; SEL 110;
NCI Metathesaurus CUI : CL545396;
Origin ID : C147562;
UMLS CUI : C4688008;
Semantic type(s)
- concept_is_in_subset
